Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Multiple Sclerosis l: Introduction

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...

Myasthenia Gravis: Overview and Treatment

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...

Open Angle Glaucoma: Treatment

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...

Antiepileptic Drugs: Glutamate Antagonists

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...

Glaucoma: Overview

Glaucoma: Overview

Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Cancer risk for multiple sclerosis patients treated with azathioprine and disease-modifying therapies: an Italian observational study.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·2021

Same author

The IN-DEEP project "INtegrating and Deriving Evidence, Experiences, Preferences": a web information model on magnetic resonance imaging for people with multiple sclerosis.

Journal of neurology·2020

Same author

Clinical outcome indicators in chronic hepatitis B and C: A primer for value-based medicine in hepatology.

Liver international : official journal of the International Association for the Study of the Liver·2019

Same author

Impact of natural menopause on multiple sclerosis: a multicentre study.

Journal of neurology, neurosurgery, and psychiatry·2019

Same author

Predictors of hospital-based multidisciplinary rehabilitation effects in persons with multiple sclerosis: a large-scale, single-centre study.

Multiple sclerosis journal - experimental, translational and clinical·2019

Same author

Clinical Application of 2017 McDonald Diagnostic Criteria for Multiple Sclerosis.

Journal of clinical neurology (Seoul, Korea)·2018

Search research articles

Related Experiment Video

Updated: Jun 13, 2026

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis

Published on: February 8, 2019

Glatiramer acetate for multiple sclerosis.

Loredana La Mantia¹, Luca M Munari, Roberta Lovati

¹Department of Neuroscience, Fondazione I.R.C.C.S. - Istituto Neurologico C. Besta, Via Celoria, 11, Milano, Italy, 20133.

The Cochrane Database of Systematic Reviews

|May 14, 2010

Summary

Glatiramer acetate shows partial efficacy in reducing relapses for relapsing-remitting multiple sclerosis (RR MS) but does not slow disease progression. It is ineffective for progressive multiple sclerosis (P MS).

Related Experiment Videos

Last Updated: Jun 13, 2026

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis

Published on: February 8, 2019

Area of Science:

Neurology
Immunology
Pharmacology

Background:

Glatiramer acetate, a synthetic amino acid polymer, has demonstrated efficacy in experimental autoimmune encephalomyelitis and in improving outcomes for multiple sclerosis (MS) patients.
Previous reviews have assessed glatiramer acetate's effectiveness, necessitating an updated analysis.

Purpose of the Study:

To evaluate the clinical efficacy of glatiramer acetate in treating patients with relapsing-remitting (RR) and progressive (P) forms of multiple sclerosis (MS).

Main Methods:

A systematic review and meta-analysis of randomized controlled trials (RCTs) comparing glatiramer acetate with placebo in definite MS patients.
Searches were conducted across multiple databases including Cochrane MS Group Trials Register, Cochrane Central Register of Controlled Trials, MEDLINE, and EMBASE up to March 2009.

Main Results:

Six RCTs involving 540 RR MS and 1049 P MS patients met the inclusion criteria.
In RR MS, glatiramer acetate showed a reduction in relapse rates and hospitalizations but no significant effect on sustained disability progression.
No benefits were observed in P MS patients, with common side effects including injection-site reactions.

Conclusions:

Glatiramer acetate demonstrates partial efficacy in RR MS by reducing relapse-related outcomes but does not significantly impact disease progression as measured by sustained disability.
The treatment is not effective for patients with progressive MS.
The high incidence of injection-site reactions raises questions about the efficacy of blinding in the included studies.